Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
DenmarkIPO:
05 February 2021Website:
http://www.evaxion-biotech.comNext earnings report:
16 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
EVAX Latest News
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results.
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Richard Ramanius - Redeye Christian Kanstrup Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results.
Evaxion Biotech (NASDAQ: EVAX ) just reported results for the fourth quarter of 2023. Evaxion Biotech reported earnings per share of -$1.60.
Evaxion Biotech (NASDAQ: EVAX ) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE: MRK ). A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech.
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by.
What type of business is Evaxion Biotech A/S?
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
What sector is Evaxion Biotech A/S in?
Evaxion Biotech A/S is in the Healthcare sector
What industry is Evaxion Biotech A/S in?
Evaxion Biotech A/S is in the Biotechnology industry
What country is Evaxion Biotech A/S from?
Evaxion Biotech A/S is headquartered in Denmark
When did Evaxion Biotech A/S go public?
Evaxion Biotech A/S initial public offering (IPO) was on 05 February 2021
What is Evaxion Biotech A/S website?
https://www.evaxion-biotech.com
Is Evaxion Biotech A/S in the S&P 500?
No, Evaxion Biotech A/S is not included in the S&P 500 index
Is Evaxion Biotech A/S in the NASDAQ 100?
No, Evaxion Biotech A/S is not included in the NASDAQ 100 index
Is Evaxion Biotech A/S in the Dow Jones?
No, Evaxion Biotech A/S is not included in the Dow Jones index
When was Evaxion Biotech A/S the previous earnings report?
No data
When does Evaxion Biotech A/S earnings report?
The next expected earnings date for Evaxion Biotech A/S is 16 August 2024